# Anticoagulants and antiplatelet drugs

## Classification

### Anticoagulants

**Parenteral**

<table>
<thead>
<tr>
<th>Anticoagulants</th>
<th>UFH</th>
<th>LMWH</th>
<th>Enoxaparin</th>
<th>Tinzaparin</th>
<th>Dalteparin</th>
<th>Certoparin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heparin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparinoids</td>
<td>Danaparoid</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hirudins</td>
<td>Lepirudin</td>
<td>Bivalirudin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pentasaccharide</td>
<td>Idraparinux</td>
<td>Fondaparinux</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Oral**

<table>
<thead>
<tr>
<th>Warfarin</th>
<th>Acenocoumarole (= nicoumalone)</th>
<th>Phenindione</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor Xa inhibitors</td>
<td>Rivaroxaban</td>
<td></td>
</tr>
<tr>
<td>Thrombin inhibitors</td>
<td>Ximelagatran (Exanta®)</td>
<td>Dabigatran (Pradaxa®)</td>
</tr>
</tbody>
</table>

### Antiplatelet drugs

<table>
<thead>
<tr>
<th>Aspirin</th>
<th>Dipyridamole</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thienopyridines</td>
<td>Clopidogrel</td>
</tr>
<tr>
<td>Ticlopidine</td>
<td></td>
</tr>
<tr>
<td>GP IIb/IIIa antagonists</td>
<td>Abciximab</td>
</tr>
<tr>
<td>Eptafibatide</td>
<td>Tirofiban</td>
</tr>
</tbody>
</table>

### Thrombolytics

For acute arterial thromboembolism – see IHD.

**Generally speaking!**

- **Anticoagulants**
  - Esp. useful in prevention/treatment of venous occlusion
  - More effective
- **Antiplatelet drugs**
  - Esp. useful in arterial occlusions (?because arterial thrombi are platelet-rich)
  - Less likely to cause haemorrhage

## Parenteral anticoagulants

### UFH

Naturally occurring mammalian mucopolysaccharides.
Molecular weight ~30kD (mean 12kD)
**Indications**

**Therapeutic** (because of rapid onset of action)
- DVT/PE
- ACS

**Prophylactic**
- DVT/PE prophylaxis
  - Surgery, esp. orthopaedics
  - Immobile patients
- Extracorporeal circuits (cardiopulmonary bypass, haemodialysis)

**Mechanism of action**

Pentasaccharide sequence: binds to natural antithrombin-III and accelerates breakdown of factor Xa 1000-fold.

18+ saccharide sequence: also accelerates factor IIa breakdown by similar mechanism

LMWHs have shorter chain lengths and accelerate factor Xa breakdown more (ca. 3-fold)

**Dosing**

**Prophylaxis**
- Low dose e.g. 5,000 units SC 8 or 12 hourly
- Monitoring not required (APTT largely unaffected)

**Treatment**
- High dose
  - Loading bolus (5,000U) plus continuous infusion (30,000-40,000U over 24 hours, or 25U/kg/h)
  - Continue until fully anticoagulated with warfarin

**Monitoring**
- APTT ratio (intrinsic + common systems) at 4-6h after starting
  - Repeat every 4-6h with dose adjustment until APTT ratio is 1.5-2.5 times control
  - If stopped, effect subsides in 2-3h

**Adverse effects**
- Bleeding
  - Reversal: 1mg protamine for 100IU UFH if within 15min of heparin, less later
- HIT (2-3%)
  - Must monitor platelets from day 5
  - UFH>>LMWH
- Osteoporosis if more than 4 months treatment
  - Esp. in pregnant women who had to swap warfarin for heparin
**Contraindications**
As NSAIDs, plus previous HIT

---

**LMWH**

LMWHs are produced by chemical (e.g. enoxaparin) or enzymatic (e.g. tinzaparin) depolymerisation of UFH. Molecular weight 2-10kD (mean 5kD).

**LMWH vs. UFH - theory**
The biological activity of heparins is related to fractional molecular weight:
- < 5.4kD mainly anti-Xa activity
- > 5.4kD both anti-Xa and anti-IIa activity

I.e. anti-IIa activity is dependent on chain length

**Pros**
- Shorter chains cleared more slowly: UFH t\(_{1/2}\) = 2-3h, enoxaparin t\(_{1/2}\) = ca. 4h (this is a con in renal failure)
- Reduced binding to plasma proteins (which compete with and reduce inhibition of antithrombin)
- Not bound by PF4 from activated platelets
- Bioavailability of fractionated heparins from SC administration is considerably higher

→ more predictable anticoagulant activity for LMWHs; no need for IV infusion (more convenient for patient and saves on nursing time – but note prophylactic heparin can be given SC, too) and no need to monitor APTT (saves on lab time and costs)

- Lower incidence of HIT
- Lower incidence of osteoporosis
- Hope of lower incidence of bleeding at equivalent antithrombotic dose has not borne out

**Cons**
- Cannot monitor APTT – need factor X ratio (expensive; no need if average body mass, n crea, short duration of use)
- Incompletely reversed by protamine (just 20%)
- Expensive (10x)

**LMWH vs. UFH - practice**
Fractionated heparins are taking over from unfractionated heparins for most of the accepted indications.

Superior efficacy proven for
- Treatment of DVT/PE
- ACS (ESSENCE trial)
- Orthopaedic lower limb surgery

But also used in
- DVT/PE prophylaxis
- Extra-corporeal circuits (unlicensed indication)

**Note**
- The different methods of preparation of LMWHs mean that there are important differences in molecular weight distribution. It is not possible to extrapolate trial data between different preparations.
- Only enoxaparin is now widely used

---

**Heparinoids**

Lower degree of sulfation

**Possible indications**
Available on named-patient basis
- DVT prophylaxis in general and orthopaedic surgery
- Severe HIT if no evidence of cross-reactivity (rare: 10%)

**Hirudins**

Specific thrombin inhibitors

<table>
<thead>
<tr>
<th>Factor IIa inhibitors</th>
<th>Don’t bind plasma proteins or PF4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Don’t rely on AT3</td>
</tr>
<tr>
<td></td>
<td>No specific antidote</td>
</tr>
</tbody>
</table>

**Indication**

Lepirudin: licensed for HIT type II

**Pentasaccharides**

New, hence still expensive and lack of experience.

Idraparinux given SC once a week; being evaluated in AF (AMADEUS trial)

**Advantages**

- Long t½ (15-20h) compared even to LMWH
- No HIT risk – does not bind PF4 or platelets

**Oral anticoagulants**

**Warfarin**

Wisconsin Alumni Research Foundation coumARIN (patent holder)

**Mechanism of action**

Structurally similar to vitamin K. Competitively inhibits vitamin K-dependent γ-carboxylation of factors II, VII, IX, X and proteins C/S.

Orally bioavailable but the onset of anticoagulation is delayed until γ-carboxylated clotting factors available in the circulation are depleted (about 72h); hence heparinise in acute situation.

Inactivated by hepatic metabolism.

**Monitoring**

By INR; can be monitored while on heparin

Issue National Anticoagulant Book, advice to show to all doctors and dentists

**Target INR**

- 2.5  DVT/PE, AF, cardioversion, DCM, mural thrombus, rheumatic heart disease
- 3.5  recurrent DVT/PE, mechanical heart valves, antiphospholipid syndrome
**Adverse effects**
- Thrombosis, esp. if protein C/S deficient
- Bleeding, esp. gut and brain
- Pregnancy
  - Early pregnancy: fetal warfarin syndrome (phocomelia, chondrodysplasia)
  - At term: placental abruption, excessive haemorrhage, neonatal hypoprothrombinaemia
- Breastfeeding OK

**Management of bleeding/↑↑INR**
Recommendations of British Society for Haematology
- Major bleeding: Vitamin K 5mg slow IV, prothrombin complex concentrate (FII/VII/IX/X = Beriplex®) 50U/kg or FFP 15ml/kg if not available
- INR<6: Reduce dose or stop and restart when INR<5
- INR 6-8: Stop and restart when INR<5
- INR>8: Stop and restart when INR<5
  - If other risk factors for bleeding: Vitamin K 0.5mg slow IV or 5mg PO,
    for partial reversal give 0.5-2.5mg of IV preparation PO

Vitamin K takes at least 6h to have any effect and can make subsequent re-warfarinisation unpredictable.

**FFP vs. PPC**
- FFP contains insufficient factors to fully reverse warfarin
  - 70kg man would require 2.5l FFP to fully reverse
  - INR misrepresents degree of reversal
- PPC
  - Easier, faster, not group dependent, and even lower risk of viral transmission
  - Main risks: thrombosis, DIC
  - Also give vitamin K

**Interactions**
If a drug is added that can affect warfarin action, more frequent monitoring is required
- Reduced absorption – cholestyramine or similar resins
- Reduced protein binding – hypoproteinaemic states e.g. nephrotic syndrome, drugs e.g. NSAIDs
- Altered clearance – P450 induction/inhibition
- Altered vitamin K availability – altered food intake, antibiotic-induced reduction in gut-derived vitamin K, laxatives
- Altered levels of clotting factors – reduced in hypermetabolic states e.g. hyperthyroidism; increased in pregnancy
- Augmented bleeding tendency – in combination with antiplatelet agents e.g. NSAIDs

**Duration of treatment**
- DVT/PE (akin to BTS guidelines)
  - Temporary risk factor 4-6w
  - First idiopathic 3-6m
  - Recurrent May be lifelong
  - Associated with pro-thrombotic state e.g. protein C/S deficiency Lifelong
- AF Lifelong
- Cardioversion 1m prior and 1m after
- Large dilated heart/cardiac aneurysm Lifelong

**Surgery in patients receiving warfarin**
- Withdraw 3-5 days pre-operatively; replace with low dose heparin
- Resume 1-3 days post-operatively

**Dental extractions**
- Omit 1-2 days prior to surgery

---

**Acenocoumarol, phenindione**

---

1 BTS multicentre trial ongoing

5/8
Use if warfarin intolerant.

**Ximelagatran (Exanta®)**

Oral thrombin inhibitor with predictable pharmacokinetics. Taken bd, metabolised to melagatran. May be a useful alternative to warfarin (SPORTIF trials showed similar efficacy in AF)

Removed from sale in 2006 due to hepatotoxicity

---

**Antiplatelet drugs**

Clinical indications include

- **CNS**
  - Prophylaxis of CVA/TIA
    - Warfarin preferred if AF/LA dilatation/mitral valve disease/LV dysfunction
  - Acute ischaemic CVA/TIA
- **Heart**
  - Prophylaxis of coronary artery disease
  - ACS
  - Following PTCA/stenting/CABG
  - AF
- **Peripheries**
  - Peripheral vascular disease

---

**Aspirin**

*Mechanism of action*

cAMP plays important role in platelet aggregation (high levels inhibit and low levels promote)

- Adenylate cyclase activity (production)
  - Stimulated by prostacyclin (PGI₂) from endothelium
  - Inhibited by thromboxane (TXA₂) from platelets
- PDE activity (degradation)

Inhibits cyclo-oxygenase by enzyme acetylation, irreversible and thus lasts life of platelet (~10 days)

Thus blocks formation of prostacyclin and thromboxane
Ideally want to block thromboxane formation but not prostacyclin; this occurs at a low dose of aspirin. Why?
- Endothelium has synthetic capacity, platelets don’t (anucleate)
- Extensive pre-systemic hydrolysis

The lower the dose, the greater the differential effect
Low-dose aspirin still affects bleeding time
<100mg takes several days for effect, hence 300mg loading dose in acute conditions

### Dipyridamole

**Mechanism**
Reversible inhibition of platelet PDE
Effect is potentiated by aspirin

**Indications**
Infrequently used
- Adjunct to PO anticoagulation for thromboembolic prophylaxis in prosthetic heart valves
- MR preparation licensed for secondary prevention in ischaemic CVA/TIA
  - European Stroke Prevention Study 2 (1996): low dose aspirin (25mg bd) plus dipyridamole (200mg bd) more effective than either agent alone for secondary prevention of stroke (end point stroke/death)
  - Risk reduction of 36% for stroke or death for combination compared to placebo
  - This combination is now available Asasantin retard
  - Used in high risk stroke patients

**Adverse effects**
Provokes myocardial ischaemia (used in chemical stress testing) \(\xrightarrow{\text{CI}}\) CI in IHD

### Thienopyridines

Prodrugs – activated in vivo
ADP antagonists at P2Y receptors
ADP is released by platelets when they adhere to collagen and provokes aggregation

**Clopidogrel**
Expensive, but more effective than aspirin
Cost implications potentially huge (>£1 vs. 1p per tablet), may cost >£100k to prevent an event

**Indications**
- Aspirin intolerance
- ACS/acute MI
  - NSTE: CURE\(^2\) (clopidogrel and aspirin vs. aspirin alone)
    - More effective at event reduction (9.3% vs. 11.4% reached end-point, \(p<0.001\))
    - Higher risk of major bleed (3.7 vs. 2.7%, \(p=0.001\)), but no significant difference in risk of life-threatening bleed (2.1% vs. 1.8%, \(p=0.13\))
  - STE: CLARITY-TIMI 28\(^3\)
- Recent MI/CVA, symptomatic PVD: CAPRIE\(^4\) (clopidogrel vs. aspirin)
  - More effective at event reduction (absolute risk reduction 3.8%)
  - Most benefit in PVD group
- Recent TIA/CVA (and additional cardiovascular risk factor): MATCH


**Ticlopidine**
Now rarely used due to adverse effects: neutropenia (1%, reversible), TTP (<0.02% but 50% mortality), diarrhoea (20%), intrahepatic cholestasis

---

**GP IIb/IIIa antagonists**

Central role of GP IIb/IIIa (integrin)

![Diagram of platelet aggregation](image-url)

All given IV; should be used by specialists only

**Indications (NICE guidance)**
- PTCA
  - In unstable angina and NSTE MI, if PTCA indicated but delayed
  - In diabetics
  - Complex procedure

Eptafibatide/tirofiban given early on; only abciximab is licensed as an adjunct to PTCA

3 distinct chemical groups:

**Monoclonal antibody (abciximab)**
- Slow dissociation from the receptor (antiplatelet effect last for ~10s hrs after administration) and immunogenic
- Beneficial in
  - Unstable angina (EPILOG-Stent) if not responding to normal Rx and scheduled for PTCA
  - High-risk angioplasty (EPIC)
- Low risk of thrombocytopenic haemorrhage – can reverse by platelet administration
- Use only once

**Peptide antagonist (eptafibatide)**
- Rapid receptor binding/dissociation and high systemic clearance

**Non-peptide antagonists (tirofiban)**
- Developed with a view to PO administration, but have failed to show clinical efficacy by this route